Conference Reports for NATAP
IDSA
ID Week 2026
October 21-24
Washington, DC
Back
 
Tweet
Low Incidence of Hepatitis B (HBV) Infection Among People Receiving Lenacapavir (LEN) or Tenofovir-Based HIV Pre-exposure Prophylaxis (PrEP) in PURPOSE 1 and PURPOSE 2